← ANALYST RATINGS · TIPRANKS
Korro Bio (KRRO): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy1 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $19.33, the highest $30.00, the lowest $10.00. The average is +127.7% from the last price of $8.49.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $9.00 → $8.50−5.6% | Hold | +0.1% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.50 → $8.00−5.9% | Sell | −5.8% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.00 → $8.50−5.6% | Hold | +0.1% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $9.50 → $8.50−10.5% | Hold | +0.1% | Upgrade | 14.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $9.50 → $8.50−10.5% | Hold | +0.1% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $9.50 → $8.50−10.5% | Hold | +0.1% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $22.00 | Buy | +159.1% | Reiterated | 06.10.26on TipRanks 08:30 | −2.7%next day +7.7% · 5 days −9.6% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $30.00 | Buy | +253.4% | Reiterated | 06.10.26on TipRanks 07:15 | −2.7%next day +7.7% · 5 days −9.6% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $15.00 | Buy | +76.7% | Reiterated | 06.10.26on TipRanks 06:30 | −2.7%next day +7.7% · 5 days −9.6% | ↗ |
| Unknown Analyst | LifeSci Capital | $21.00 | Buy | +147.3% | Reiterated | 06.10.26on TipRanks 06:30 | −2.7%next day +7.7% · 5 days −9.6% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $21.00 | Buy | +147.3% | Reiterated | 09.09.26on TipRanks Sep 10 06:10 | −3.8%next day +1.6% · 5 days +8.1% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $10.00 | Hold | +17.8% | Reiterated | 07.08.26on TipRanks 21:45 | +1.8%next day −0.9% · 5 days −2.5% | ↗ |
| William Maughan★★★★★★★★★★#1398 · hits 46% · avg +16.2% | Clear Street | $18.00 | Buy | +112.0% | Reiterated | 07.08.26on TipRanks 05:30 | +8.7%next day +1.8% · 5 days −0.2% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $22.00 | Buy | +159.1% | Reiterated | 06.08.26on TipRanks Aug 7 09:06 | +5.6%next day +8.7% · 5 days +8.4% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | +5.6%next day +8.7% · 5 days +8.4% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $15.00 | Buy | +76.7% | Reiterated | 06.08.26on TipRanks 21:50 | +8.7%next day +1.8% · 5 days −0.2% | ↗ |
| Catherine Novack★★★★★★★★★★#905 · hits 41% · avg +25.1% | JonesTrading | $23.00 | Buy | +170.9% | Upgrade | 08.05.26on TipRanks 10:35 | −7.3%next day −5.1% · 5 days −15.7% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | $23.00 | Buy | +170.9% | Upgrade | 13.03.26on TipRanks 05:45 | +11.9%next day −2.6% · 5 days −14.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Korro Bio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.00 at a price of $9.91 (+91.7%); now: $19.33 at $8.49 (+127.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 5 | 5 | 3 | 4 | 9 |
| Buy | 6 | 3 | 3 | 5 | 5 | 5 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.26 (from $-2.04 to $-0.93). Last quarter: $-1.07.
Sales
Next quarter’s sales estimate — $0M (from $0M to $2M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Korro Bio
- CEO: Ram Aiyar
- Employees: 57
- 60 First Street, Cambridge, MA, 02141, US
- www.korrobio.com
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Data from the stock’s TipRanks forecast page, read 8 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗